2,741 reports of this reaction
5.2% of all TICAGRELOR reports
#2 most reported adverse reaction
MYOCARDIAL INFARCTION is the #2 most commonly reported adverse reaction for TICAGRELOR, manufactured by AstraZeneca Pharmaceuticals LP. There are 2,741 FDA adverse event reports linking TICAGRELOR to MYOCARDIAL INFARCTION. This represents approximately 5.2% of all 52,671 adverse event reports for this drug.
TICAGRELOR has an overall safety score of 85 out of 100. Patients taking TICAGRELOR who experience myocardial infarction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYOCARDIAL INFARCTION is moderately reported among TICAGRELOR users, representing a notable but not dominant share of adverse events.
In addition to myocardial infarction, the following adverse reactions have been reported for TICAGRELOR:
The following drugs have also been linked to myocardial infarction in FDA adverse event reports:
MYOCARDIAL INFARCTION has been reported as an adverse event in 2,741 FDA reports for TICAGRELOR. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYOCARDIAL INFARCTION accounts for approximately 5.2% of all adverse event reports for TICAGRELOR, making it one of the most commonly reported side effect.
If you experience myocardial infarction while taking TICAGRELOR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.